Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20839386 | 1.00 | RAB9A (0.51) | RAB9AHPGDKDM4EGAAMAPT | |
| SCHEMBL30055558 | 1.00 | RAB9A (0.51) | RAB9AHPGDKDM4EGAAMAPT | |
| SCHEMBL30055862 | 0.90 | RAB9A (0.48) | RAB9AHPGDKDM4EGAAMAPT | |
| SCHEMBL20839131 | 0.90 | RAB9A (0.48) | RAB9AHPGDKDM4EGAAMAPT | |
| SCHEMBL20839132 | 0.90 | RAB9A (0.48) | RAB9AHPGDKDM4EGAAMAPT | |
| SCHEMBL20839144 | 0.89 | RAB9A (0.56) | RAB9AHPGDKDM4EGAAMAPT | |
| SCHEMBL20839143 | 0.89 | RAB9A (0.56) | RAB9AHPGDKDM4EGAAMAPT | |
| SCHEMBL30056166 | 0.89 | RAB9A (0.56) | RAB9AHPGDKDM4EGAAMAPT | |
| SCHEMBL30360884 | 0.89 | PTGS2 (0.53) | RAB9AHPGDKDM4EGAAMAPT | |
| SCHEMBL20839068 | 0.84 | RAB9A (0.49) | RAB9AHPGDKDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-01 | — | — | US | claimed |
| CN-111386261-B | Coumarin derivatives, process for their preparation and their use in the treatment of cancer | 利德发现中心有限责任公司 | 2024-03-22 | — | — | CN | claimed |
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| EP-3684762-B1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2021-09-07 | — | — | US | claimed |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-09-17 | — | — | US | claimed |
| EP-3684762-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | Lead Discovery Center GmbH (DE) | 2020-07-29 | — | — | EP | claimed |
| CN-111386261-A | Coumarin derivatives, preparation method thereof and application thereof in cancer treatment | 利德发现中心有限责任公司 | 2020-07-07 | — | — | CN | claimed |
| WO-2019057821-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2019-03-28 | — | — | WO | claimed |
| CN-111386261-B | Coumarin derivatives, process for their preparation and their use in the treatment of cancer | 利德发现中心有限责任公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3684762-B1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-3684762-B1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2021-09-07 | — | — | US | disclosed |
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2021-09-07 | — | — | US | disclosed |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2020-09-17 | — | — | US | disclosed |
| EP-3684762-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | Lead Discovery Center GmbH (DE) | 2020-07-29 | — | — | EP | disclosed |
| CN-111386261-A | Coumarin derivatives, preparation method thereof and application thereof in cancer treatment | 利德发现中心有限责任公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2019057821-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019057821-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | TFAM, POLRMT, TUFM | RAB9A 4733/4885HPGD 1853/4885KDM4E 1030/4885 |
| US-11111238-B2 | Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer | POLRMT, UQCRC2, UQCRC1 | RAB9A 4204/4885HPGD 947/4885KDM4E 2362/4885 |
| US-20200291011-A1 | COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER | POLRMT, UQCRC2, UQCRC1 | RAB9A 4204/4885HPGD 947/4885KDM4E 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.